Clinical Trial Update: Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating ferric carboxymaltose for iron deficiency in heart failure with preserved ejection fraction has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Iron Deficiency

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Cantonal Hosptal, Baselland | Conditions: Heart Failure With Normal Ejection Fraction, Iron-deficiency | Phase 4 | Status: WITHDRAWN